Anakinra treatment in patients with Familial Mediterranean Fever: a single-center experience

Uğurlu, Serdal; Ergezen, B.; Özdoğan, Huri

doi:10.1186/1546-0096-13-s1-p123

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…anti-IL-1 biological treatments) supports the efficacy results observed during the pivotal phase 3 trial (Table 3) [14][15][16][17][18][19]. Decreases in FMF attack frequency [14][15][16][17][18], CRP levels [14,16,17,19], and/or reduction of disease activity [15][16][17]19] were reported with anti-IL-1 treatment across six studies that each included ≥ 20 patients treated with anakinra (Table 3). Improvements were also reported across all 36-item short form survey (SF-36) QoL domains following anti-IL-1 treatment in one study (Table 3) [18].…”

Section: What Is the Efficacy Of Anakinra In Fmf?supporting

confidence: 64%

“…Real-world experience with anakinra and canakinumab (i.e. anti-IL-1 biological treatments) supports the efficacy results observed during the pivotal phase 3 trial (Table 3) [14][15][16][17][18][19]. Decreases in FMF attack frequency [14][15][16][17][18], CRP levels [14,16,17,19], and/or reduction of disease activity [15][16][17]19] were reported with anti-IL-1 treatment across six studies that each included ≥ 20 patients treated with anakinra (Table 3).…”

Section: What Is the Efficacy Of Anakinra In Fmf?mentioning

confidence: 55%

“…Anakinra was preferred for on-demand treatment over canakinumab in this study due to its shorter response time and half-life. In the four patients with menstruationtriggered FMF attacks, who were instructed to administer Table 3 Efficacy of anakinra in familial Mediterranean fever in real-world studies that each included ≥ 20 patients treated with anakinra Where reported, pts generally received ANA 100 mg/day [14,[16][17][18][19], with a few pts receiving lower [14,17] or higher [14,17,19] dosages; or CAN 150 mg every 4 [18,19], 8 [14,16,17,19] or 12 [14] weeks, or CAN 300 mg every 4 weeks [19] ANA anakinra, BL baseline, CAN canakinumab, CL CR creatinine clearance, COL colchicine, CRP C-reactive protein, FMF familial Mediterranean fever, GFR glomerular filtration rate, mo months, NR not reported, phys physicians, pt(s) patient(s), QoL quality of life, SAA serum amyloid A, SF-36 36-item short form survey (↑ scores indicate ↑ QoL), VAS visual analogue scale, ↓ decrease, ↑ increase/higher *p < 0.05, **p ≤ 0.001 vs BL a COL use: 0.5-4 mg/day (in 95% of pts) [14], mean 2.34 mg/day (in 92% of pts) [15], 0.5-2.5 mg/day (in 88% of pts) [16], 0.5-3 (mean 1.5) mg/ day [17], mean 1.23 mg/day [19] or NR [ anakinra daily for 3 days from the first day of menstruation, no attacks were reported during 15 months of follow-up, and improvements in CRP levels and QoL were observed. The efficacy of on-demand treatment in the other two patients was not reported [21].…”

Section: Can Anakinra Be Used On-demand?mentioning

confidence: 99%

See 2 more Smart Citations

Anakinra in familial Mediterranean fever: a profile of its use

Lee

Blair

2021

Drugs Ther Perspect

View full text Add to dashboard Cite

The list of approved indications for anakinra (Kineret ® ), an anti-interleukin (IL)-1 biological, has been expanded in the EU to include Familial Mediterranean fever (FMF). The pathology of FMF is associated with excess production of IL-1, thus IL-1 blockade with anakinra was investigated as a treatment for FMF. Results from a phase 3 clinical trial and real-world experience in patients with FMF demonstrated reductions in FMF attack frequency, improvements in quality of life and reductions in serum amyloid A (SAA) and C-reactive protein (CRP) levels. Efficacy was also observed in patients with FMF and amyloidosis in the real-world setting; nevertheless, concurrent use of colchicine with anti-IL-1 biologicals is recommended to prevent and/or halt the progression of amyloidosis. Anakinra was generally well tolerated during the phase 3 clinical trial, with comparable proportions of patients with adverse reactions in the anakinra and placebo groups. Furthermore, the safety profile of anakinra in FMF was consistent with that established in other indications, based on all available evidence.

show abstract

Section: What Is the Efficacy Of Anakinra In Fmf?supporting

confidence: 64%

Section: What Is the Efficacy Of Anakinra In Fmf?mentioning

confidence: 55%

Section: Can Anakinra Be Used On-demand?mentioning

confidence: 99%

See 1 more Smart Citation

Anakinra in familial Mediterranean fever: a profile of its use

Lee

Blair

2021

Drugs Ther Perspect

View full text Add to dashboard Cite

show abstract

“…Anakinra is another established therapeutic in the treatment of auto-inflammatory diseases in rheumatology. Notably, it has been successfully used in patients with Familial Mediterranean Fever (FMF) [118,119], an auto-inflammatory disease associated with mutations in the inflammasome component pyrin that results in triggering inflammasome activation [120,121]. The therapeutic use of anakinra for treating acute gout attacks in CKD patients is currently in clinical trials (ASGARD study), with the results yet to be published [117].…”

Section: Inflammasome Inhibition As a Potential Therapeutic Targetmentioning

confidence: 99%

Pigment Nephropathy: Novel Insights into Inflammasome-Mediated Pathogenesis

Giuliani

Kassianos

Healy

et al. 2019

IJMS

View full text Add to dashboard Cite

Pigment nephropathy is an acute decline in renal function following the deposition of endogenous haem-containing proteins in the kidneys. Haem pigments such as myoglobin and haemoglobin are filtered by glomeruli and absorbed by the proximal tubules. They cause renal vasoconstriction, tubular obstruction, increased oxidative stress and inflammation. Haem is associated with inflammation in sterile and infectious conditions, contributing to the pathogenesis of many disorders such as rhabdomyolysis and haemolytic diseases. In fact, haem appears to be a signalling molecule that is able to activate the inflammasome pathway. Recent studies highlight a pathogenic function for haem in triggering inflammatory responses through the activation of the nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome. Among the inflammasome multiprotein complexes, the NLRP3 inflammasome has been the most widely characterized as a trigger of inflammatory caspases and the maturation of interleukin-18 and -1β. In the present review, we discuss the latest evidence on the importance of inflammasome-mediated inflammation in pigment nephropathy. Finally, we highlight the potential role of inflammasome inhibitors in the prophylaxis and treatment of pigment nephropathy.

show abstract

“…Mediterranean Fever (FMF) [122,123], an auto-inflammatory disease associated with mutations in the inflammasome component pyrin that results in triggering inflammasome activation [124,125].…”

Section: Anti-il-1β and Il-1 Receptor Antagonistsmentioning

confidence: 99%

Pigment Nephropathy: Novel Insights into Inflammasome-Mediated Pathogenesis

Giuliani

Kassianos

Healy

et al. 2019

Preprint

View full text Add to dashboard Cite

Pigment nephropathy is an acute decline in renal function following the deposition of endogenous haem-containing proteins in the kidneys. Haem pigments such as myoglobin and haemoglobin are filtered by glomeruli and absorbed by the proximal tubules. They cause renal vasoconstriction, tubular obstruction, increased oxidative stress and inflammation. Haem is associated with inflammation in sterile and infectious conditions, contributing to the pathogenesis of many disorders such as rhabdomyolysis and haemolytic diseases. In fact, haem appears to be a signaling molecule that is able to activate the inflammasome pathway. Recent studies highlight a pathogenic function for haem in triggering inflammatory responses through the activation of the nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome. Among the inflammasome multiprotein complexes, the NLRP3 inflammasome has been the most widely characterized as a trigger of inflammatory caspases and the maturation of interleukin-18 and -1β. In the present review, we discuss the latest evidence on the importance of inflammasome-mediated inflammation in pigment nephropathy. Finally, we highlight the potential role of inflammasome inhibitors in the prophylaxis and treatment of pigment nephropathy.

show abstract

Anakinra treatment in patients with Familial Mediterranean Fever: a single-center experience

Cited by 4 publications

References 0 publications

Anakinra in familial Mediterranean fever: a profile of its use

Anakinra in familial Mediterranean fever: a profile of its use

Pigment Nephropathy: Novel Insights into Inflammasome-Mediated Pathogenesis

Pigment Nephropathy: Novel Insights into Inflammasome-Mediated Pathogenesis

Contact Info

Product

Resources

About